Evidence map›Paper›PMID 23509733›Full record

ArticleBioMed research international2013

RNase P-associated external guide sequence effectively reduces the expression of human CC-chemokine receptor 5 and inhibits the infection of human immunodeficiency virus 1.

Wenbo Zeng, Gia-Phong Vu, Yong Bai, Yuan-Chuan Chen, Phong Trang, Sangwei Lu, Gengfu Xiao, Fenyong Liu

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Wenbo ZengState Key Laboratory of Virology, College of Life Sciences, Wuhan University, Hubei, Wuhan 430072, China.
Gia-Phong Vu
Yong Bai
Yuan-Chuan Chen
Phong Trang
Sangwei Lu
Gengfu Xiao
Fenyong Liu
University of California, Berkeley · USWuhan University · CN

Funding

RIBOZYMES FOR STUDIES AND TREATMENT OF HCMV INFECTIONSR01AI041927 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI LIU, FENYONG · 1997 to 2012
$3.7M
Small RNA therapeutics for AIDS-associated infectionR01DE014842 · NIDCR · UNIVERSITY OF CALIFORNIA BERKELEY · PI LIU, FENYONG · 2002 to 2010
$2.2M
Bacteria Based Agents for Therapy of AIDS Associated InfectionsR01AI091536 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI LU, SANGWEI · 2011 to 2014
$1.3M
NIAID NIH HHS R01 AI041927NIAID NIH HHS R01-AI041927NIAID NIH HHS R01 AI091536NIAID NIH HHS R01-AI091536NIDCR NIH HHS R01 DE014842NIDCR NIH HHS R01-DE014842
6 · The paper itself

Abstract

External guide sequences (EGSs) represent a new class of RNA-based gene-targeting agents, consist of a sequence complementary to a target mRNA, and render the target RNA susceptible to degradation by ribonuclease P (RNase P). In this study, EGSs were constructed to target the mRNA encoding human CC-chemokine receptor 5 (CCR5), one of the primary coreceptors for HIV. An EGS RNA, C1, efficiently directed human RNase P to cleave the CCR5 mRNA sequence in vitro. A reduction of about 70% in the expression level of both CCR5 mRNA and protein and an inhibition of more than 50-fold in HIV (R5 strain Ba-L) p24 production were observed in cells that expressed C1. In comparison, a reduction of about 10% in the expression of CCR5 and viral growth was found in cells that either did not express the EGS or produced a "disabled" EGS which carried nucleotide mutations that precluded RNase P recognition. Furthermore, the same C1-expressing cells that were protected from R5 strain Ba-L retained susceptibility to X4 strain IIIB, which uses CXCR4 as the coreceptor instead of CCR5, suggesting that the RNase P-mediated cleavage induced by the EGS is specific for the target CCR5 but not the closely related CXCR4. Our results provide direct evidence that EGS RNAs against CCR5 are effective and specific in blocking HIV infection and growth. These results also demonstrate the feasibility to develop highly effective EGSs for anti-HIV therapy.

Indexed as

CCR5 Receptor AntagonistsGene Expression RegulationAnti-HIV AgentsCell LineGene Expression Regulation, ViralHeLa CellsHIV-1HumansMolecular Targeted TherapyMutationNucleic Acid ConformationPromoter Regions, GeneticProtein BindingRibonuclease PRNA InterferenceRNA, MessengerAnti-HIV AgentsCCR5 Receptor AntagonistsRibonuclease PRNA, Messenger

Identifiers

PMID23509733
PMCPMC3591226
OpenAlexW2059004991

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.